-- Pulmicort Generics Win a Negative for Teva, Canaccord Says
-- B y   L e s l i e   P i c k e r
-- 2013-04-02T13:25:03Z
-- http://www.bloomberg.com/news/2013-04-02/pulmicort-generics-win-a-negative-for-teva-canaccord-says.html
U.S. court ruling allowing generic
versions of AstraZeneca’s Pulmicort asthma treatment may spur 2%
reduction in Teva EPS for 3 quarters and greater hit in 2014,
Canaccord Genuity analysts led by  Randall Stanicky  wrote in e-
mailed note.
*Teva likely to lose royalty back to AstraZeneca
*Teva reaffirmed hold, $45 pt
**NOTE: AstraZeneca May Appeal U.S. Patent Ruling on Pulmicort
Respules NSN MKMET76JTSEN <GO>  To contact the reporter on this story:
Leslie Picker in  New York  at 
 lpicker2@bloomberg.net   To contact the editor responsible for this story:
Emma O’Brien at 
 eobrien6@bloomberg.net  